Revenue Breakdown
Composition ()
No data
Revenue Streams
China Pharma Holdings Inc (CPHI) generates its revenue primarily from Domestic Pharmaceuticals, which accounts for 100.0% of total sales, equivalent to $756.22K. Understanding this concentration is critical for investors evaluating how CPHI navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, China Pharma Holdings Inc maintains a gross margin of -7.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -83.06%, while the net margin is -86.15%. These profitability ratios, combined with a Return on Equity (ROE) of -42.98%, provide a clear picture of how effectively CPHI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CPHI competes directly with industry leaders such as ADIL and GLMD. With a market capitalization of $3.48M, it holds a significant position in the sector. When comparing efficiency, CPHI's gross margin of -7.89% stands against ADIL's N/A and GLMD's N/A. Such benchmarking helps identify whether China Pharma Holdings Inc is trading at a premium or discount relative to its financial performance.
